

# **Screening Libraries**

**Proteins** 

# **Product** Data Sheet

# TGF beta 2/TGFB2 Protein, Mouse/Rat (HEK293)

Cat. No.: HY-P70649

Synonyms: TGFB2; BSC-1 cell growth inhibitor; Cetermin; Glioblastoma-derived T-cell suppressor factor; G-

TSF; MGC116892; Polyergin; TGF-beta-2; TGF-beta-2; transforming growth factor beta-2

Mouse;Rat Species: Source: **HEK293** 

Accession: P27090 (A303-S414)

21808 Gene ID:

Molecular Weight: Approximately 12.0 kDa

# **PROPERTIES**

ΛΛ	Sac	iuen	-
AA	Sec	ıueı	ıce

ALDAAYCFRN VQDNCCLRPL YIDFKRDLGW KWIHEPKGYN ANFCAGACPY LWSSDTQHTK VLSLYNTINP EASASPCCVS QDLEPLTILY YIGNTPKIEQ LSNMIVKSCK C.S

**Biological Activity** 

Measured by its ability to inhibit the IL-4-dependent proliferation of HT⊠2 mouse T cells. The ED<sub>50</sub> for this effect is <0.2 ng/mL.

**Appearance** 

Lyophilized powder.

**Formulation** 

Lyophilized from a 0.2 μm filtered solution of 4 mM HCl.

**Endotoxin Level** 

<1 EU/µg, determined by LAL method.

Reconsititution

It is not recommended to reconstitute to a concentration less than 100 μg/mL in 4 mM HCl. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Storage & Stability

Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Shipping

Room temperature in continental US; may vary elsewhere.

# **DESCRIPTION**

Background

In mammals, three different isoforms of TGF-β are described (TGF-β1, TGF-β2 and TGF-β3; transforming growth factor beta) to regulate apoptosis, proliferation, differentiation, migration and invasion processes utilising overlapping but not redundant mechanisms. All three isoforms are expressed in the liver, but their expression is differentially distributed among liver cell types. TGF-β2 expression in different liver cell types and is also associated with developmental defects and fibrotic diseases in  $mice^{[1][2][3]}$ .

The sequence of amino acids in TGF-β2 proteins from different species is very stable, which leads to the conclusion that in

Page 1 of 2

the process of evolution, TGF-β2 has been only slightly altered, and that both in humans and in animals, its function is similar.

TGF $\beta$ 2 is a transforming growth factor beta (TGFB) family cytokine, with members of this cytokine family playing broad regulatory roles and controlling key physiological processes including cell migration, proliferation and differentiation via signalling through type I and type II receptors (TGF $\beta$ R1 and TGF $\beta$ R2), with signals propagating via the downstream regulatory SMAD proteins. This TGF $\beta$ /SMAD pathway is frequently dysregulated in human cancer. TGF $\beta$  cytokines are capable of suppressing T cell growth in response to IL $\Delta$ 2. The degree of TGF $\beta$ 2 expression correlated with the expression of several different markers of immune cell subsets within tumours. In addition, TGF- $\beta$ 2 regulates embryonic development and, therefore not surprisingly, global Tgfb2 null mice exhibit a wide range of developmental defects and perinatal mortality [1][2][3]

TGF- $\beta$ 2 is an immune suppressor involved in the development of immune tolerance, and recombinant TGF- $\beta$ 2 incubation is more potent than TGF- $\beta$ 1 or TGF- $\beta$ 3 in suppressing macrophage inflammatory responses. TGF- $\beta$ 2 is shown to correlate with bad prognosis in intrahepatic CCAs and hepatocellular carcinoma. Mechanistically, canonical Smad signalling as well as crosstalk with Yap, Hippo, Wnt and  $\beta$ -catenin signalling have been demonstrated in the liver and other organs<sup>[1][2][3]</sup>.

# **REFERENCES**

- [1]. Hirokazu Takahashi, et al. TGF-82 is an exercise-induced adipokine that regulates glucose and fatty acid metabolism. Nat Metab. 2019 Feb;1(2):291-303.
- [2]. Zunqiang Xiao, et al. TGFβ2 is a prognostic-related biomarker and correlated with immune infiltrates in gastric cancer. J Cell Mol Med. 2020 Jul;24(13):7151-7162.
- [3]. Anne Dropmann, et al. TGF-B2 silencing to target biliary-derived liver diseases. Gut. 2020 Sep;69(9):1677-1690.
- [4]. Dona T Wu, et al. TGF-beta concentration specifies differential signaling profiles of growth arrest/differentiation and apoptosis in podocytes. J Am Soc Nephrol. 2005 Nov;16(11):3211-21.
- [5]. F J Kelly, et al. Acute and chronic renal effects of recombinant human TGF-beta2 in the rat. J Am Soc Nephrol. 1999 Jun;10(6):1264-73.
- [6]. B van't Land, et al. Transforming Growth Factor-beta2 protects the small intestine during methotrexate treatment in rats possibly by reducing stem cell cycling. Br J Cancer, 2002 Jul 1;87(1):113-8.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

 $\hbox{E-mail: } tech@MedChemExpress.com$ 

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA